Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K31/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/198742SUPERPARAMAGNETIC MODIFIED NEUTROPHIL EXOSOME BIONIC VESICLE DRUG DELIVERY BIOLOGICAL PREPARATION AND PREPARATION METHOD THEREFOR
WO 29.09.2022
Int.Class A61K 47/69
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
69the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Appl.No PCT/CN2021/089946 Applicant JIANGSU UNIVERSITY Inventor ZHANG, Xu
A superparamagnetic modified neutrophil exosome bionic vesicle drug delivery biological preparation and a preparation method therefor, characterized in that, the preparation method comprises the following steps: 1) co-culturing peripheral blood neutrophils and anti-tumor drugs to obtain neutrophils uptaking drugs; 2) centrifuging the neutrophils uptaking drugs, and re-suspending a bottom buffer pad to obtain a cell suspension; 3) performing continuous physical extrusion and gradient filtration on the cell suspension to obtain a neutrophil exosome bionic vesicle-coated drug suspension, the gradient filtration comprising sequentially passing through 1 μm, 400 nm, and 200 nm of polycarbonate filter membranes; 4) re-suspending a bottom NNV-drug buffer pad after centrifugation of the neutrophil exosome bionic vesicle-coated drug suspension to obtain an NNV-drug suspension; and 5) mixing the NNV-drug suspension with a superparamagnetic material, co-incubating, and performing magnetic separation on the co-incubated mixed solution to obtain the superparamagnetic modified neutrophil exosome bionic vesicle drug delivery biological preparation.
2.WO/2022/199627POLYCYCLIC COMPOUNDS AND USES THEREOF
WO 29.09.2022
Int.Class C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No PCT/CN2022/082548 Applicant NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING Inventor WANG, Xiaodong
Provided herein are polycyclic compounds, compositions, and methods for modulating the PDE3A activity or regulating the interaction of PDE3A/SLFN12. The compounds modulate the PDE3A activity or regulate the interaction of PDE3A/SLFN12, and are useful as antitumor agents.
3.WO/2022/203197MOTHER-CUSTOMIZED PRETERM-BIRTH PREVENTING PESSARY AND METHOD FOR MANUFACTURING SAME
WO 29.09.2022
Int.Class A61F 6/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
6Contraceptive devices; Pessaries; Applicators therefor
06for use by females
08Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception
Appl.No PCT/KR2022/002070 Applicant THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION Inventor MIN, Jae Young
The present invention relates to a mother-customized preterm-birth preventing pessary and a method for manufacturing same and, more specifically, to a mother-customized preterm-birth preventing pessary for preventing a preterm birth and a method for manufacturing same. In order to accomplish the above-mentioned purpose, the present invention provides a mother-customized pessary for preventing a preterm birth, comprising: a pessary body provided to support the lower part of the uterus; a secretion hole formed in the pessary body; a cylinder which is coupled to the pessary body and stores fluid to be discharged via the secretion hole; and a controller which is provided to control the discharge of the fluid stored in the cylinder, in response to any one or more pieces of information of the gestational age of the mother, the length of the cervix, and the pressure applied to the pessary body.
4.WO/2022/201187A PROCESS FOR THE PREPARATION OF MIXED OXYBATE SALTS AND POLYMORPHS THEREOF
WO 29.09.2022
Int.Class A61K 31/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
Appl.No PCT/IN2022/050271 Applicant ALKEM LABORATORIES LIMITED Inventor PARIHAR, Jayprakash Ajitsingh
The present invention provides an improved scalable process for preparation of mixed oxybate salts. More particularly, the present invention provides a process of preparation of a mixture of sodium, potassium, magnesium and calcium oxybate salts. Further, the present invention provides polymorphs of each of the individual salts and the mixed salt along with the methods of preparation of each.
5.WO/2022/200857PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS
WO 29.09.2022
Int.Class A61K 31/454
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
454containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
Appl.No PCT/IB2022/000150 Applicant MONTE ROSA THERAPEUTICS AG Inventor GAVORY, Gerald
The present disclosure relates to a. compound of formula I or a. pharmaceutically acceptable salt thereof Formula I wherein A is Formula II X1 is linear or branched C1-6 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, 4-8 membered heterocycloalkyl, wherein X1 is unsubstituted or substituted with one or more of halogen, linear or branched C1-6 alkyl, linear or branched C1-6 heteroalkyl, CF3, CHF2, CMeF2, -O-CHF2, -O-(CH2)2-OMe, OCF3, C1-6 alkylamino, -CN, -N(H)C(O)-C1-6alkyl, - OC(O)-C1-6alkyl, -OC(O)-C1-4alkylamino, -C(O)O-C1-6alkyl, -COOH, -CHO, -C1-6alkylC(O)OH, -C1-6alkylC(O)O-C1-6alkyl, NH2, C1-6 alkoxy or Cue alkylhydroxy; or X1 together with X4 forms a 4-8 membered heterocycloalkyl, which is unsubstituted or substituted with one or more of halogen, linear or branched -C1-6 alkyl, CF3, CHF2, CMeF2, -O-(CH2)2-OMe, OCF3, OCHF2, C1-6 alkylamino, -CN, -N(H)C(O)-C1-6 alkyl, -OC(O)-C1-6alkyl, -C(O)O-C1-6alkyl, -COOH, -C1-6alkylC(O)OH, -C1-6alkylC(O)O-C1-6alkyl, NH2, C1-4 alkylhydroxy, or C1-4 alkoxy; X2 is hydrogen, C3-6 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, 4-8 membered heterocycloalkyl, wherein X2 is unsubstituted or substituted with one or more of linear or branched Cue alkyl, -C1-4 alkoxy, NH2, NMe2, halogen, CF3, CHF2, CMeF2, -O-(CH2)2-OMe, OCF3, OCHF2, CM alkylhydroxy, X3 is -NH-, -O-; X4 is -NH-, - CH2-; L1 is a covalent bond, C1-6 alkyl, which is unsubstituted or substituted with one or more of C1-4 alkyl, halogen; L2 is a covalent bond, Cue alkyl, which is unsubstituted or substituted with one or more of CM alkyl, halogen; L3 is a covalent bond, -O-, - C1-4 alkoxy or C1-6 alkyl, which is unsubstituted or substituted with one or more of C1-4 alkyd, halogen, for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codons in a monotherapy or in a combined therapy with an aminoglycoside or a. pharmaceutically acceptable salt thereof.
6.WO/2022/200542FLAVONOID POLYAMINES AND THEIR USE TREATING CENTRAL NERVOUS SYSTEM DISORDERS
WO 29.09.2022
Int.Class A61K 31/352
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
352condensed with carbocyclic rings, e.g. cannabinols, methantheline
Appl.No PCT/EP2022/057856 Applicant FLORATEK PHARMA SA Inventor STOICESCU, Dan Florin
The present invention relates to the use of chromen-4-one derivatives, and to salts, multi-salts, solvates, prodrugs thereof, for the treatment and prevention of a disease, disorder or condition associated with neurotrophic pathways function or is a mitochondrial disease. In particular, the present invention relates to the use of such compounds in the treatment and prevention of central nervous system diseases/disorders.
7.WO/2022/200557COMBINATION TREATMENTS FOR MELANOMA
WO 29.09.2022
Int.Class A61K 31/5355
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
5355Non-condensed oxazines containing further heterocyclic rings
Appl.No PCT/EP2022/057895 Applicant ASTRAZENECA AB Inventor SMITH, Simon Andrew
Combination Treatments for Melanoma This specification discloses the use of an ATR inhibitor in combination with an immune checkpoint inhibitor for the treatment of melanoma in a patient who has previously received immunotherapy.
8.WO/2022/200632MICRORNA-134 INHIBITORS
WO 29.09.2022
Int.Class A61K 31/712
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
712Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
Appl.No PCT/EP2022/058140 Applicant NEUMIRNA THERAPEUTICS APS Inventor KAUPPINEN, Markus Sakari
The present invention provides novel highly potent antisense oligonucleotides. Such compounds are useful for making pharmaceutical compositions for treatment of a range of diseases where modulation of miR-134 activity is beneficial, including neurological diseases such as epilepsy.
9.WO/2022/201832SCREENING METHOD FOR GLP-1 SECRETION CONTROL AGENT, GLP-1 SECRETION CONTROL AGENT, COMPOSITION FOR PREVENTING OR AMELIORATING DIABETES, OBESITY, POSTPRANIDAL HYPERGLYCEMIA, NEURODEGENERATIVE DISEASE, HYPOGLYCEMIA, ADIPOSITY, OR NESIDIOBLASTOSIS, METHOD FOR PROMOTING SECRETION OF GLP-1 IN GPR84-EXPRESSING CELLS, METHOD FOR PRODUCING COMPOSITION FOR PROMOTING SECRETION OF GLP-1, USE OF GPR84 AGONIST FOR PRODUCING THERAPEUTIC AGENT FOR DISEASE, GLP-1 SECRETION PROMOTION AGENT, AND COMPOSITION FOR ORAL INGESTION
WO 29.09.2022
Int.Class C12Q 1/06
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
02involving viable microorganisms
04Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
06Quantitative determination
Appl.No PCT/JP2022/002650 Applicant THE NISSHIN OILLIO GROUP, LTD. Inventor KIMURA Ikuo
The present invention addresses the problem of providing a novel GLP-1 secretion promotion agent. The present invention provides a GLP-1 secretion promotion agent that includes a GPR84 agonist as an active ingredient.
10.WO/2022/202477PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR SIDE EFFECTS OF ANTHRACYCLINE ANTICANCER AGENT
WO 29.09.2022
Int.Class A61K 31/197
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
195having an amino group
197the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
Appl.No PCT/JP2022/011540 Applicant KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION Inventor IKEDA, Masataka
[Problem] To provide a safe prophylactic agent or therapeutic agent for side effects of an anthracycline anticancer agent, the agent having a broad range of applications. [Solution] In a treatment of a cancer using an anthracycline anticancer agent, 5-aminolevulinic acid is used in combination.